Class Action Filed Against Unicycive Over Alleged Misleading Statements
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. by Levi & Korsinsky, LLP on behalf of investors who claim to have been misled by the company's statements between March 29, 2024 and June 27, 2025. Investors have until October 14, 2025 to join the lawsuit, with no cost or obligation to participate.
The lawsuit alleges that Unicycive Therapeutics and its executives made false claims or hid information about the company's readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application. The complaint covers a period of over two years, from March 29, 2024 to June 27, 2025.
Moving forward, the case could involve various stages such as court hearings, discovery phases, settlement negotiations, or even a trial, depending on its status and the court's procedural schedule. This timeline begins after October 14, 2025.
Investors who suffered losses during the specified time frame are encouraged to take action by October 14, 2025. They can request the court to appoint them as lead plaintiff in the case, with no financial burden or commitment required for participation in the lawsuit.
Read also:
- Crooked House Pub's Demolition: Council Orders Rebuild, Debate on Historic Building Protections
- Shaping India's Economic Progression: Readying the Financial System for Tomorrow
- Conflict between Ben & Jerry's co-founder and Unilever over Gaza issues leads to resignation of co-founder
- Two farmers in Zambia take legal action against two firms with Chinese connections, alleging an ecological disaster caused by their operations.
